decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
pharma · Acute Myeloid Leukemia · Advanced Hematologic Malignancy · FHTX
Foghorn Therapeutics
Foghorn Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Watertown, USA HQ
2016 Founded
124 Employees
Public company Type
FHTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Watertown, USA
- Founded
- 2016
- Employees
- 124
- Programs
- 5
- Drugs
- 2
- Patents
- 14
Foghorn Therapeutics pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Foghorn Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Foghorn Therapeutics in public FDA and regional records.